The CARTITUDE-2 phase 2 trial aimed to investigate the long-term efficacy and safety of cilta-cel in patients with R/R MM who received ≤3 prior lines of therapy. The primary endpoint was to determine MRD. Researchers noticed that Cilta-cel demonstrates long-term efficacy and safety in patients with MM, which is crucial for nurse-managed care. […]...
ONS 2024
Coverage of 49th Annual Congress of Oncology Nursing Society
Apr 24
-Apr 28, 2024